RYTM Rhythm Pharmaceuticals, Inc.
XNAS
115.00
+0.92%
Pre-market
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
RYTM
$115.00
▲ +0.92%
What changed
Recent filings, trades and movesKey stats
$113.95
Pre-market
$115.00
+0.92%
- 52-Week Range
- $74.50 – $122.20
- YTD
- +8.51%
- IV Rank (30D)
- 82.28
- Straddle Price
- $19.00
- P/C Vol Ratio
- 0.77
- Market Cap
- $7.9B
- Open
- $113.42
- Day Range
- $112.50 – $115.06
- Volume
- 616,031
- Prev Close
- $113.94
Fair Value
MODEL: NEUTRAL
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.84% |
| Beta vs SPY | 1.26 |
| Cost of Equity (CAPM) | 10.82% (VRP-adj) |
| WACC | 11.35% |
| Volatility Risk Premium | -17.0pp (IV − HV30), ERP adj -25bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +30.0% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -98.4% |
| Book / Price | 2.6% |
| Gross Margin (TTM) | 88.2% |
| FCF Margin (TTM) | -29.6% |
| Debt / Equity | 0.44 |
| Quality Score | 3/6 — normal (10y DCF) |
| SMA 50 | $96.29 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $93.79 |
| Bollinger Width / SMA20 | 37.3% (drives anchor stability) |
| Net Debt | $0.0B |
| Market Cap | $8B |
Peers used for multiples: ABBV, GILD, INSM, ISRG, LLY, MRK, NTRA, NVO
60-Day Conviction
6%
20-Day Fair Value
≈ by Dec 9, 2026
$113.48
α -0.4%
rank 16%
conviction
33%
40-Day Fair Value
≈ by Jan 7, 2027
$115.38
α +1.3%
rank 16%
conviction
45%
60-Day Fair Value
≈ by Feb 5, 2027
$113.72
α -0.2%
rank 16%
conviction
6%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 52.0× · 4 peers |
| Peer EV/EBITDA | n/a | 0% | median 30.0× · 5 peers |
| Peer P/B | $58.34 | 23% | median 20.0× · 6 peers |
| Peer P/S | $61.81 | 23% | median 13.8× · 7 peers |
| Market Anchor (SMA50) | $96.29 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | $113.89 | 54% | 18 strikes · skew +0.23 |
As of 2026-11-10 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $7.9B
- Employees
- 414
- List Date
- 2017-10-05
- CIK
- 0001649904
- Last Earnings
- Nov 3 before open · −7.5% vs ±11.9% expected
- Headquarters
- Boston, MA
- Homepage
- https://www.rhythmtx.com
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is …
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 1.09% | -30.55% | -4.50% | -2.26% | -1.07% | -2.37% | -6.61% |
| Feb | -15.18% | -0.52% | -11.12% | -6.28% | -7.57% | -14.92% | -9.26% |
| Mar | -20.75% | 35.69% | -30.99% | -0.87% | 1.09% | -8.39% | -4.04% |
| Apr | -3.06% | -46.86% | 8.44% | -6.84% | 30.38% | -7.67% | -4.27% |
| May | -10.66% | -45.40% | -17.57% | -13.88% | -3.87% | 7.96% | -13.90% |
| Jun | 0.26% | 23.15% | -3.96% | 8.48% | -0.74% | 26.36% | 8.92% |
| Jul | -16.55% | 193.02% | 10.60% | 12.98% | 30.24% | -10.25% | 36.67% |
| Aug | -25.32% | 81.53% | 14.33% | 0.96% | 16.82% | 3.26% | 15.26% |
| Sep | -3.26% | -3.31% | -17.54% | 14.02% | -3.09% | -9.09% | -3.71% |
| Oct | -12.07% | 6.16% | 4.57% | -7.80% | 13.75% | -0.90% | 0.62% |
| Nov | -26.03% | 2.25% | 39.35% | 26.59% | -4.09% | 21.95%* | 10.00% |
| Dec | 15.78% | 7.85% | 36.05% | -7.99% | 1.90% | -- | 10.72% |
| Total | -73.21% | 101.69% | 3.95% | 10.38% | 88.50% | -2.41% | 21.48% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $95.15
SMA 50: $96.44
SMA 200: $97.12
Current: $113.95
EMA 12: $102.56
EMA 26: $98.18
MACD: 4.3788 | Signal: 3.0885
BULLISH
ADX (14): 28.12
TREND
+DI: 33.14
−DI: 15.68
Momentum Oscillators
RSI (14): 68.13
NEUTRAL
Stoch %K: 96.80
Stoch %D: 93.56
Williams %R: -3.31
Volume & Volatility
BB Upper: $114.39
BB Lower: $75.92
NEUTRAL
OBV: 26,892,722
Vol SMA 20: 1,734,988
Vol ROC: 53.94%
ATR: $5.48
True Range: $2.56
HV 20: 99.7%
HV 30: 83.9%
HV 60: 63.9%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-12T00:00:00 – 2026-11-10T00:00:00
AI Analysis
Written before RYTM’s Nov 3 earnings report, so it doesn’t reflect the results.
LLM Stock Analysis Report
Executive Summary
BULLISH (Confidence Level: 7/10)
Key drivers:
- Technical trend indicators aligning with bullish sentiment
- Low volatility, indicating a relatively calm market environment
- Recent positive news headlines supporting the stock's upward movement
Primary risks:
- Bearish momentum signals from MACD and Stochastic %K
- High put/call volume ratio indicating bearish sentiment in options market
- Risk of mean reversion from overbought RSI reading
Investment thesis: RYTM is likely to continue its short-term uptrend, driven by positive news headlines and low volatility. However, caution should be exercised due to the bearish momentum signals and high put/call volume ratio.
Recent news sentiment impact: The overall sentiment has been neutral-to-positive in recent weeks, with only one negative headline highlighting CFO Smith's sale of shares. This has had a limited impact on the stock price.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): Uptrend (Price above SMA 20 and EMA 12)
- Medium-term (1-3 months): Neutral (RSI reading indicates neutral momentum)
- Long-term (3-12 months): Bullish (SMA 200 and EMA 26 indicating upward trajectory)
Support/Resistance Levels:
- Upper Bollinger Band: $106.57
- Middle Bollinger Band: $97.64
- Lower Bollinger Band: $88.71
Momentum Signals: RSI: 41.67 (neutral), MACD: bearish, Stochastic %K: 27.75 (bearish), Williams %R: -63.43 (oversold)
Volume Analysis:
- Volume SMA 20: 767220.67
- On-Balance Volume (OBV): 17213953.97
- Volume Rate of Change: -1.91%
News & Sentiment Analysis
Recent Headlines Summary: Neutral-to-positive headlines in recent weeks, with one negative article highlighting CFO Smith's share sale.
Sentiment Assessment: Positive sentiment prevails, driven by the overall neutral-to-positive news headlines.
Catalyst Identification: Earnings announcement scheduled for Q2 2026, potential product launch in H1 2026.
Market Narrative: The market narrative is generally positive, with RYTM's stock price responding to the recent positive news headlines. However, caution should be exercised due to the bearish momentum signals and high put/call volume ratio.
Risk & Volatility Assessment
Risk Assessment:
- Beta: 0.64 (low volatility relative to SPY)
- Alpha: 0.64 (similar performance to market)
Volatility Regime: Current volatility is low, indicating a relatively calm market environment.
Options Market Signals: IV Rank: 24.0% (Low), Current IV: 79.9%, Expected Move: $19.30 (42 DTE), Put/Call Volume Ratio: 3.09 (Bearish sentiment)
Downside Protection: Support levels: SMA 20 and EMA 12, Bollinger Bands' lower band: $88.71
Market Context & Positioning
Sector Performance: RYTM is performing relatively well within its sector, with a beta of 0.64 indicating low volatility relative to the market.
Institutional Activity: High institutional interest, as indicated by the high volume flow and open interest in options contracts.
Correlation Analysis: R-squared: 0.21 (low correlation), indicating that RYTM's stock price movements are not strongly correlated with the overall market.
Relative Valuation: Position within a trading range, with potential for further upward movement.
Key Levels & Action Items
Critical Price Levels:
- Upper Bollinger Band: $106.57
- Middle Bollinger Band: $97.64
- Lower Bollinger Band: $88.71
Breakout/Breakdown Levels: Price above SMA 20 and EMA 12 could trigger further upward movement, while price below SMA 50 and EMA 26 could indicate a bearish reversal.
Time-Sensitive Catalysts:
- Earnings announcement scheduled for Q2 2026
- Potential product launch in H1 2026
Risk Management: Stop-loss levels: SMA 20 and EMA 12, position sizing considerations: use of stop-loss orders to limit potential losses.
Generated
News
All RYTM news →
Rhythm specializes in treatments for metabolic conditions and severe obesity.
Japan launch and U.S. demand lifted sales sharply this quarter.
Earnings History
21 of 22 under expected move
Avg Expected Move
14.61%
Avg Actual Move
6.44%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-02-03 | Pre-Market | 7.09% | 1.35% | 0.19x | Within |
| 2021-08-03 | Pre-Market | 7.75% | 4.54% | 0.59x | Within |
| 2021-11-02 | Pre-Market | 17.77% | 6.61% | 0.37x | Within |
| 2022-03-01 | Pre-Market | 16.40% | 11.42% | 0.70x | Within |
| 2022-08-02 | Pre-Market | 25.46% | 13.82% | 0.54x | Within |
| 2023-05-02 | Pre-Market | 22.27% | 7.27% | 0.33x | Within |
| 2023-08-01 | Pre-Market | 42.04% | 27.52% | 0.65x | Within |
| 2023-11-07 | Pre-Market | 17.17% | 0.52% | 0.03x | Within |
| 2024-02-22 | Pre-Market | 15.37% | 9.73% | 0.63x | Within |
| 2024-05-07 | Pre-Market | 9.34% | 10.32% | 1.10x | Exceeded |
| 2024-08-06 | Pre-Market | 15.78% | 0.02% | 0.00x | Within |
| 2024-11-05 | Pre-Market | 9.20% | 6.15% | 0.67x | Within |
| 2025-01-10 | Pre-Market | 10.22% | 2.31% | 0.23x | Within |
| 2025-02-26 | Pre-Market | 14.26% | 4.49% | 0.31x | Within |
| 2025-05-07 | Pre-Market | 8.41% | 3.06% | 0.36x | Within |
| 2025-08-05 | Pre-Market | 9.86% | 1.85% | 0.19x | Within |
| 2025-11-04 | Pre-Market | 12.22% | 7.69% | 0.63x | Within |
| 2026-01-09 | Pre-Market | 6.64% | 3.65% | 0.55x | Within |
| 2026-02-26 | Pre-Market | 16.24% | 1.09% | 0.07x | Within |
| 2026-05-05 | Pre-Market | 12.74% | 7.86% | 0.62x | Within |
| 2026-08-04 | Pre-Market | 13.38% | 2.92% | 0.22x | Within |
| 2026-11-03 | Pre-Market | 11.88% | 7.49% | 0.63x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
RYTM Options Activity & IV Rank
RYTM IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 63.7%
7-DTE IV: 56.1%
Expected Move: $19.00
7-DTE Move: $8.60
Days to Exp: 38 (2026-12-18)
Options Flow · All expiries
Call Volume: 686
Put Volume: 528
P/C Volume: 0.77
NEUTRAL
Call OI: 5,820
Put OI: 2,063
P/C OI: 0.354
Total OI: 7,883
ATM Options Pricing
ATM Call: $9.30
ATM Put: $9.70
Call %: 8.2%
Put %: 8.5%
Chain Summary
Chain Volume: 1,214
Chain OI: 7,883
Last Updated: 11/10/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
HIGH γ vs HISTORY
Estimated net dealer gamma is at the 83rd percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
83%
vs own history
GEX tilt
+0.76
OI-weighted, today
Vanna tilt
-0.03
δ-sensitivity to IV
Charm tilt
-0.34
δ-decay vs time
Charm tilt -0.34: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 17 ATM contracts, 3k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Nov 10 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Nov 10 · No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)16.3LowNov 10
IV Rank (30 DTE)82.3HighNov 10
Straddle Price (30 DTE)$19.00Nov 10
Beta Analysis
Risk Metrics
Beta: 1.2647
Alpha: 16.26%
Correlation: 0.3178
R-Squared: 10.1%
Stock Volatility: 54.4%
Market Volatility: 13.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own RYTM
6 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $140.3M | #293 of 6285 | -10.9% | 13F | |
| Point72 Hedge fund Steve Cohen | $46.0M | #352 of 1945 | -51.1% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $35.2M | #800 of 3716 | -29.9% | 13F | |
| Duquesne Family Office Family office Stanley Druckenmiller | $22.6M | #39 of 86 | new | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $7.6M | #1208 of 3138 | -73.5% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $660K | #1936 of 4729 | +22.7% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
RYTM Institutional Ownership (13F)
Filings for 2026-06-30 · 110 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 68,136,442 (as of 2026-09-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
5 filers$17.89M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $10.99M | 61.44% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $3.11M | 17.38% | 2026-06-30 |
| 3 | Jane Street Group, LLC Custodian | $3.01M | 16.82% | 2026-06-30 |
| 4 | IMC-Chicago, LLC Custodian | $723.63K | 4.04% | 2026-09-30 |
| 5 | Simplex Trading, LLC Custodian | $57.13K | 0.32% | 2026-09-30 |
6 filers$11.19M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $5.36M | 47.93% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $2.66M | 23.82% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $1.94M | 17.37% | 2026-06-30 |
| 4 | Simplex Trading, LLC Custodian | $590.33K | 5.28% | 2026-09-30 |
| 5 | IMC-Chicago, LLC Custodian | $428.47K | 3.83% | 2026-09-30 |
| 6 | GROUP ONE TRADING LLC Custodian | $199.85K | 1.79% | 2026-06-30 |
RYTM Insider Trading (Form 4)
Latest: 2026-09-14Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-14 | David P Meeker | President and CEO | Mixed Sell −50,000 · Exer +50,000 |
— | $54.36 | -$4.83M | EDGAR |
| 2026-09-01 | Hunter C Smith | Chief Financial Officer | Mixed Sell −62,774 · Exer +57,187 |
−5,587 | $67.48 | -$5.15M | EDGAR |
| 2026-08-18 | Manher Joshi | Chief Medical Officer | Grant (A) | +75,000 opt | — | EDGAR | |
| 2026-08-17 | Alastair Garfield | Chief Scientific Officer | Sell (S) | −7,763 | $117.57 | -$912.7K | EDGAR |
| 2026-08-17 | Joseph Shulman | Chief Technical Officer | Mixed Exer +2,024 · Sell −5,079 |
−3,055 | $87.56 | -$594.4K | EDGAR |
| 2026-08-14 | Jennifer Kayden Lee | EVP, Head of North America | Mixed Sell −75,834 · Exer +56,601 |
−19,233 | $74.74 | -$7.90M | EDGAR |
| 2026-08-14 | Yann Mazabraud | EVP, Head of International | Mixed Sell −57,000 · Exer +46,625 |
−10,375 | $66.95 | -$6.30M | EDGAR |
| 2026-07-02 | Alastair Garfield | Chief Scientific Officer | Mixed Exer +4,445 · Tax −2,150 |
+2,295 | $110.41 | -$237.4K | EDGAR |
| 2026-06-25 | Jennifer L Good | Director | Exer (M) | +4,712 | — | EDGAR | |
| 2026-06-25 | David W J McGirr | Director | Exer (M) | +4,712 | — | EDGAR | |
| 2026-06-25 | Lynn A. Tetrault | Director | Exer (M) | +4,712 | — | EDGAR | |
| 2026-06-25 | Christophe Jean | Director | Exer (M) | +4,712 | — | EDGAR | |
| 2026-06-25 | Stuart A Arbuckle | Director | Exer (M) | +4,712 | — | EDGAR | |
| 2026-06-24 | Lynn A. Tetrault | Director | Mixed Sell −37,000 · Exer +37,000 |
— | $64.30 | -$2.67M | EDGAR |
| 2026-05-20 | Hunter C Smith | Chief Financial Officer | Exer (M) | +3,000 | $17.87 | $53.6K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
RYTM Insider Holdings
14 insiders · @ $113.95
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | David P Meeker | President and CEO | 252,073 | $28.72M | -$10.15M | 18 | 2026-09-14 |
| 2 | Hunter C Smith | Chief Financial Officer | 114,024 | $12.99M | -$19.42M | 46 | 2026-09-01 |
| 3 | Yann Mazabraud | EVP, Head of International | 55,655 | $6.34M | -$12.88M | 25 | 2026-08-14 |
| 4 | Jennifer Kayden Lee | EVP, Head of North America | 54,233 | $6.18M | -$16.94M | 27 | 2026-08-14 |
| 5 | Pamela J. Cramer | Chief Human Resources Officer | 34,107 | $3.89M | -$10.98M | 30 | 2026-02-13 |
| 6 | Edward T Mathers | Director | 21,168 | $2.41M | $0 | 14 | 2026-03-16 |
| 7 | Joseph Shulman | Chief Technical Officer | 15,915 | $1.81M | -$15.75M | 33 | 2026-08-17 |
| 8 | David W J McGirr | Director | 11,712 | $1.33M | -$4.27M | 12 | 2026-06-25 |
| 9 | Jennifer L Good | Director | 11,712 | $1.33M | -$4.27M | 13 | 2026-06-25 |
| 10 | Christophe Jean | Director | 11,712 | $1.33M | $0 | 11 | 2026-06-25 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
RYTM Board & Officers
As of SEC filings through Sep 14, 2026Directors 7
- Christophe Jean · since Oct 4, 2017
- David P Meeker · since Oct 4, 2017
- David W J McGirr · since Oct 4, 2017
- Jennifer L Good · since Jun 19, 2019
- Stuart A Arbuckle · since Jul 23, 2019
- Lynn A. Tetrault · since Dec 9, 2020
- Kimberly J Popovits · since Apr 1, 2026
Officers 9
- David P Meeker · President and CEO · listed since Jul 2020
- Hunter C Smith · Chief Financial Officer · listed since Jul 2020
- Pamela J. Cramer · Chief Human Resources Officer · since Jul 26, 2021
- Joseph Shulman · Chief Technical Officer · since Feb 9, 2022
- Alastair Garfield · Chief Scientific Officer · since Jul 8, 2024
- Manher Joshi · Chief Medical Officer · since Aug 17, 2026
- Yann Mazabraud · EVP, Head of International · since Oct 5, 2020
- Jennifer Kayden Lee · EVP, Head of North America · since Nov 9, 2020
- Christopher Paul German · Corporate Controller & CAO · since Aug 11, 2023
Changes in the last 10 years (90)
| Aug 17, 2026 | Manher Joshi became Chief Medical Officer |
| Apr 1, 2026 | The company announced the departure of Edward T Mathers from the board in an SEC filing |
| Apr 1, 2026 | Kimberly J Popovits became a director |
| Dec 16, 2025 | The company announced the departure of Camille L Bedrosian from the board in an SEC filing |
| Jul 8, 2024 | Alastair Garfield became Chief Scientific Officer |
| Aug 11, 2023 | Christopher Paul German became Corporate Controller & CAO |
| Aug 4, 2023 | The company announced the departure of William T. Roberts as Chief Accounting Officer in an SEC filing |
| Feb 9, 2022 | Joseph Shulman became Chief Technical Officer |
| Sep 10, 2021 | Linda Shapiro Manning became Chief Medical Officer |
| Jul 26, 2021 | Pamela J. Cramer became Chief Human Resources Officer |
| Dec 9, 2020 | Lynn A. Tetrault became a director |
| Dec 9, 2020 | Camille L Bedrosian became a director |
| Dec 4, 2020 | Rajeev M. Shah reported in an SEC filing no longer being a 10% owner |
| Dec 4, 2020 | Ra Capital Management, L.p. reported in an SEC filing no longer being a 10% owner |
| Dec 4, 2020 | RA Capital Healthcare Fund LP reported in an SEC filing no longer being a 10% owner |
| Dec 4, 2020 | Peter Kolchinsky reported in an SEC filing no longer being a 10% owner |
| Nov 9, 2020 | Jennifer Kayden Lee became EVP, Head of North America |
| Oct 5, 2020 | Yann Mazabraud became EVP, Head of International |
| Jul 21, 2020 | Hunter C Smith listed as Chief Financial Officer (previously CFO and Interim CEO) in SEC filings |
| Jul 21, 2020 | David P Meeker first listed as President and CEO in an SEC filing |
| Jun 29, 2020 | Rajeev M. Shah first on file as a 10% owner |
| Mar 31, 2020 | Hunter C Smith listed as CFO and Interim CEO (previously Chief Financial Officer) in SEC filings |
| Mar 29, 2020 | William T. Roberts became Chief Accounting Officer |
| Oct 16, 2019 | Ra Capital Management, L.p. became a 10% owner |
| Oct 16, 2019 | RA Capital Healthcare Fund LP became a 10% owner |
| Oct 16, 2019 | Peter Kolchinsky became a 10% owner |
| Jul 23, 2019 | Stuart A Arbuckle became a director |
| Jun 19, 2019 | Jennifer L Good became a director |
| Oct 15, 2018 | Murray Stewart became Chief Medical Officer |
| Sep 6, 2018 | Hunter C Smith listed as Chief Financial Officer (previously CFO and Treasurer) in SEC filings |
| Jun 8, 2018 | Todd Foley no longer listed as a 10% owner in SEC filings |
| Jun 6, 2018 | Simon Kelner became Chief Human Resources Officer |
| May 24, 2018 | Orbimed Advisors LLC reported in an SEC filing no longer being a 10% owner |
| May 24, 2018 | OrbiMed Capital GP V LLC reported in an SEC filing no longer being a 10% owner |
| Oct 10, 2017 | Pfizer Inc reported in an SEC filing no longer being a 10% owner |
| Oct 10, 2017 | Ipsen, S.A. reported in an SEC filing no longer being a 10% owner |
| Oct 10, 2017 | Hadley Harbor Master Investors (Cayman) L.P. reported in an SEC filing no longer being a 10% owner |
| Oct 6, 2017 | Julian Baker reported in an SEC filing no longer being a 10% owner |
| Oct 6, 2017 | Felix Baker reported in an SEC filing no longer being a 10% owner |
| Oct 6, 2017 | Baker Bros. Advisors LP reported in an SEC filing no longer being a 10% owner |
| Oct 6, 2017 | Baker Bros. Advisors (GP) LLC reported in an SEC filing no longer being a 10% owner |
| Oct 4, 2017 | Trv Gp, LLC became a 10% owner |
| Oct 4, 2017 | Todd Foley became a director |
| Oct 4, 2017 | Todd Foley became a 10% owner |
| Oct 4, 2017 | Third Rock Ventures LP became a 10% owner |
| Oct 4, 2017 | Third Rock Ventures GP, L.P. became a 10% owner |
| Oct 4, 2017 | Scott D Sandell became a 10% owner |
| Oct 4, 2017 | Samuel D Isaly became a 10% owner |
| Oct 4, 2017 | Robert I Tepper became a 10% owner |
| Oct 4, 2017 | Ravi Viswanathan became a 10% owner |
| Oct 4, 2017 | Ploeg Leonardus H.T. Van der became Chief Scientific Officer |
| Oct 4, 2017 | Pfizer Inc became a 10% owner |
| Oct 4, 2017 | Peter J Barris became a 10% owner |
| Oct 4, 2017 | Patrick J Kerins became a 10% owner |
| Oct 4, 2017 | Orbimed Advisors LLC became a 10% owner |
| Oct 4, 2017 | OrbiMed Capital GP V LLC became a 10% owner |
| Oct 4, 2017 | Nithya Desikan became Chief Commercial Officer |
| Oct 4, 2017 | New Enterprise Associates 13 LP became a 10% owner |
| Oct 4, 2017 | Neil Exter became a director |
| Oct 4, 2017 | NEA Partners 13, Limited Partnership became a 10% owner |
| Oct 4, 2017 | NEA 13 GP, Ltd became a 10% owner |
| Oct 4, 2017 | Mpm Bioventures V, L.p. became a 10% owner |
| Oct 4, 2017 | Mpm Bioventures V LLC became a 10% owner |
| Oct 4, 2017 | Mpm Bioventures V Gp LLC became a 10% owner |
| Oct 4, 2017 | Mpm Asset Management Investors Bv5 LLC became a 10% owner |
| Oct 4, 2017 | Mark J Levin became a 10% owner |
| Oct 4, 2017 | M James Barrett became a 10% owner |
| Oct 4, 2017 | Luke Evnin became a 10% owner |
| Oct 4, 2017 | Kevin P Starr became a 10% owner |
| Oct 4, 2017 | Keith Michael Gottesdiener became a director |
| Oct 4, 2017 | Keith Michael Gottesdiener became CEO and President |
| Oct 4, 2017 | Julian Baker became a 10% owner |
| Oct 4, 2017 | Jonathan Silverstein left the board, per their own SEC filing |
| Oct 4, 2017 | Jonathan Silverstein is no longer a 10% owner, per their own SEC filing |
| Oct 4, 2017 | Jonathan Silverstein became a director |
| Oct 4, 2017 | Jonathan Silverstein became a 10% owner |
| Oct 4, 2017 | Ipsen, S.A. became a 10% owner |
| Oct 4, 2017 | Hunter C Smith became CFO and Treasurer |
| Oct 4, 2017 | Hadley Harbor Master Investors (Cayman) L.P. became a 10% owner |
| Oct 4, 2017 | Fred T. Fiedorek became Chief Medical Officer |
| Oct 4, 2017 | Forest Baskett became a 10% owner |
| Oct 4, 2017 | Felix Baker became a 10% owner |
| Oct 4, 2017 | Edward T Mathers became a director |
| Oct 4, 2017 | David W J McGirr became a director |
| Oct 4, 2017 | David P Meeker became a director |
| Oct 4, 2017 | David M Mott became a 10% owner |
| Oct 4, 2017 | Christophe Jean became a director |
| Oct 4, 2017 | Baker Bros. Advisors LP became a 10% owner |
| Oct 4, 2017 | Baker Bros. Advisors (GP) LLC became a 10% owner |
| Oct 4, 2017 | Ansbert Gadicke became a 10% owner |
Not reported recently (32)
- Linda Shapiro Manning · Last reported as Chief Medical Officer in an SEC filing dated Feb 11, 2022
- Todd Foley · Last reported as a director in an SEC filing dated Mar 16, 2021
- Simon Kelner · Last reported as Chief Human Resources Officer in an SEC filing dated Feb 16, 2021
- Murray Stewart · Last reported as Chief Medical Officer in an SEC filing dated Feb 16, 2021
- Nithya Desikan · Last reported as Chief Commercial Officer in an SEC filing dated Sep 1, 2020
- Keith Michael Gottesdiener · Last reported as a director in an SEC filing dated Mar 11, 2020
- Ploeg Leonardus H.T. Van der · Last reported as Chief Scientific Officer in an SEC filing dated Jun 3, 2019
- Kevin P Starr · Last reported as a 10% owner in an SEC filing dated Sep 4, 2018
- Third Rock Ventures LP · Last reported as a 10% owner in an SEC filing dated Sep 4, 2018
- Mark J Levin · Last reported as a 10% owner in an SEC filing dated Sep 4, 2018
- Third Rock Ventures GP, L.P. · Last reported as a 10% owner in an SEC filing dated Sep 4, 2018
- Trv Gp, LLC · Last reported as a 10% owner in an SEC filing dated Sep 4, 2018
- Robert I Tepper · Last reported as a 10% owner in an SEC filing dated Sep 4, 2018
- Neil Exter · Last reported as a director in an SEC filing dated Jun 8, 2018
- Fred T. Fiedorek · Last reported as Chief Medical Officer in an SEC filing dated Feb 16, 2018
- Mpm Bioventures V LLC · Last reported as a 10% owner in an SEC filing dated Oct 11, 2017
- Mpm Bioventures V Gp LLC · Last reported as a 10% owner in an SEC filing dated Oct 11, 2017
- Mpm Bioventures V, L.p. · Last reported as a 10% owner in an SEC filing dated Oct 11, 2017
- Mpm Asset Management Investors Bv5 LLC · Last reported as a 10% owner in an SEC filing dated Oct 11, 2017
- Ansbert Gadicke · Last reported as a 10% owner in an SEC filing dated Oct 11, 2017
- Luke Evnin · Last reported as a 10% owner in an SEC filing dated Oct 11, 2017
- Scott D Sandell · Last reported as a 10% owner in an SEC filing dated Oct 10, 2017
- Ravi Viswanathan · Last reported as a 10% owner in an SEC filing dated Oct 10, 2017
- NEA 13 GP, Ltd · Last reported as a 10% owner in an SEC filing dated Oct 10, 2017
- New Enterprise Associates 13 LP · Last reported as a 10% owner in an SEC filing dated Oct 10, 2017
- NEA Partners 13, Limited Partnership · Last reported as a 10% owner in an SEC filing dated Oct 10, 2017
- David M Mott · Last reported as a 10% owner in an SEC filing dated Oct 10, 2017
- Patrick J Kerins · Last reported as a 10% owner in an SEC filing dated Oct 10, 2017
- Forest Baskett · Last reported as a 10% owner in an SEC filing dated Oct 10, 2017
- Peter J Barris · Last reported as a 10% owner in an SEC filing dated Oct 10, 2017
- M James Barrett · Last reported as a 10% owner in an SEC filing dated Oct 10, 2017
- Samuel D Isaly · Last reported as a 10% owner in an SEC filing dated Oct 10, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
RYTM Proposed Insider Sales (Form 144)
Latest: 2026-09-14
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
8 filings
· $30.5M notice value
· 7 unique filers
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Jennifer Kayden Lee (1, $8.9M) · HUNTER SMITH (1, $6.7M) · YANN MAZABRAUD (1, $6.4M) · David Meeker (1, $5.2M) · PAMELA CRAMER (2, $1.7M)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-09-14 | David Meeker | Director, Officer | 50,000 | $5.24M | 2026-09-14 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-31 | HUNTER SMITH | Officer | 62,774 | $6.73M | 2026-08-31 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-13 | ALASTAIR GARFIELD | Officer | 7,763 | $912.9K | 2026-08-13 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-13 | JOSEPH J SHULMAN | Officer | 5,079 | $597.3K | 2026-08-13 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-13 | Jennifer Kayden Lee | Officer | 75,834 | $8.92M | 2026-08-13 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-12 | YANN MAZABRAUD | Officer | 57,000 | $6.43M | 2026-08-12 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-11 | PAMELA CRAMER | Officer | 11,406 | $1.32M | 2026-08-11 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-10 | PAMELA CRAMER | Officer | 3,520 | $407.0K | 2026-08-10 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-06-22 | LYNN TETRAULT | Director | 37,000 | $3.58M | 2026-06-22 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-03-04 | CAMILLE L BEDROSIAN | Director | 64,540 | $5.85M | 2026-03-04 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-03
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
ETF Holders
70 ETFs hold RYTM
25 shown · $1.10B total exposure · 0.21% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.01% | $208.4M | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.22% | $168.7M | $77.9B | 2026-11-06 |
| 3 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.08% | $147.5M | — | 2026-09-30 |
| 4 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 1.34% | $138.0M | $10.3B | 2026-11-06 |
| 5 | VBK Vanguard Morningstar Small-Cap Growth ETF | Vanguard | 0.19% | $82.2M | — | 2026-09-30 |
| 6 | VXF Vanguard Extended Market ETF | Vanguard | 0.07% | $66.5M | — | 2026-09-30 |
| 7 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.45% | $61.4M | $14.2B | 2026-11-06 |
| 8 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.51% | $56.0M | $11.2B | 2026-11-06 |
| 9 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.18% | $32.0M | — | 2026-09-30 |
| 10 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.14% | $31.5M | — | 2026-08-31 |
| 11 | JGRO JPMorgan Active Growth ETF | JPMorgan | 0.24% | $22.6M | $9.3B | 2026-11-09 |
| 12 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.28% | $18.5M | $6.6B | 2026-11-06 |
| 13 | VHT Vanguard Health Care ETF | Vanguard | 0.07% | $16.0M | — | 2026-09-30 |
| 14 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.01% | $9.5M | $95.6B | 2026-11-06 |
| 15 | SMLF iShares U.S. Small-Cap Equity Factor ETF | iShares (BlackRock) | 0.14% | $6.0M | $4.3B | 2026-11-06 |
| 16 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.36% | $6.0M | — | 2026-09-30 |
| 17 | TMSL T. Rowe Price Small-Mid Cap ETF | Nport | 0.19% | $5.2M | — | 2026-06-30 |
| 18 | LABU Direxion Daily S&P Biotech Bull 3X ETF | Direxion | 0.90% | $5.1M | — | 2026-11-09 |
| 19 | VT Vanguard Total World Stock ETF | Vanguard | 0.00% | $4.6M | — | 2026-09-30 |
| 20 | SCHB Schwab U.S. Broad Market ETF | Nport | 0.01% | $4.1M | — | 2026-08-31 |
| 21 | MSSM Morgan Stanley Pathway Small-Mid Cap Equity ETF | Nport | 0.46% | $3.3M | — | 2026-08-31 |
| 22 | FHLC Fidelity MSCI Health Care Index ETF | Fidelity | 0.08% | $3.2M | $4.0B | 2026-11-06 |
| 23 | RSSL Global X Russell 2000 ETF | Global X | 0.22% | $3.2M | — | 2026-11-09 |
| 24 | GSC Goldman Sachs Small Cap Equity ETF | Goldman | 1.03% | $3.2M | $305.0M | 2026-11-06 |
| 25 | JHMM John Hancock Multifactor Mid Cap ETF | Nport | 0.04% | $2.0M | — | 2026-06-30 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-2.90
TTM Revenue
$280.75M
TTM Net Income
$-198.30M
TTM Op. Cash Flow
$-81.79M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q3 '26 | 2026-09-30 | $92.13M | $-42.35M | $-0.61 | $-3.06M |
| Q2 '26 | 2026-06-30 | $71.25M | $-50.36M | $-0.73 | $-9.15M |
| Q1 '26 | 2026-03-31 | $60.11M | $-56.74M | $-0.83 | $-44.19M |
| Q4 '25 | 2025-12-31 | $57.25M | $-48.84M | $-0.73 | $-25.39M |
| Q3 '25 | 2025-09-30 | $51.30M | $-54.28M | $-0.82 | $-26.62M |
| Q2 '25 | 2025-06-30 | $48.50M | $-47.98M | $-0.75 | $-23.31M |
| Q1 '25 | 2025-03-31 | $32.70M | $-50.82M | $-0.81 | $-40.35M |
| Q4 '24 | 2024-12-31 | $41.83M | $-44.63M | $-0.72 | $-18.84M |
| Q3 '24 | 2024-09-30 | $33.25M | $-44.97M | $-0.73 | $-25.21M |
| Q2 '24 | 2024-06-30 | $29.08M | $-33.56M | $-0.55 | $-29.08M |
| Q1 '24 | 2024-03-31 | $25.97M | $-141.37M | $-2.35 | $-40.74M |
| Q4 '23 | 2023-12-31 | $24.23M | $-41.63M | $-0.70 | $-29.38M |
Q3 2026 • period ending 2026-09-30 • filed 2026-11-03
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
74.08
P/S
31.80
EV/EBITDA
—
EV/Sales
31.92
ROE
-204.1%
ROA
-48.1%
Div Yield
0.02%
FCF Yield
-1.38%
Debt/Equity
0.91
Current Ratio
—
Market Cap
$7.63B
as of 2026-11-10
RYTM vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| LLY Eli Lilly & Co. | $1.26T | 46.5 | +45.5% | +32.6% | 27 |
| ABBV ABBVIE INC. | $518.4B | 50.6 | +10.7% | +28.2% | 33 |
| MRK Merck & Co., Inc. | $366.7B | 152.6 | +4.9% | +39.1% | 49 |
| GILD Gilead Sciences Inc | $210.0B | — | +6.5% | +40.5% | 43 |
| NVO Novo-Nordisk A/S | $182.4B | — | — | −22.3% | 20 |
| ISRG Intuitive Surgical Inc. | $159.7B | 54.4 | +20.5% | −19.9% | 16 |
| NTRA Natera, Inc. Common Stock | $46.5B | — | +36.6% | +36.3% | 40 |
| INSM Insmed, Inc. | $25.5B | — | +240.0% | −32.5% | 36 |
| RYTM Rhythm Pharmaceuticals, Inc. Common Stoc | $7.9B | — | +61.0% | +8.5% | 82 |
| Peer median | $196.2B | 52.5 | +20.5% | +30.4% | 35 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
11.00M
SI % of Float
17.09%
Days to Cover
13.48
Short Vol Ratio
55.2%
Free Float
64.39M
Float %
94.0%
Short interest 2026-10-15 • Short volume 2026-11-10 • Float 2026-08-07